寨卡病毒药物发现策略。
Strategies for Zika drug discovery.
机构信息
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Department of Phamarcology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
出版信息
Curr Opin Virol. 2019 Apr;35:19-26. doi: 10.1016/j.coviro.2019.01.005. Epub 2019 Mar 7.
Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.
寨卡病毒（ZIKV）可导致孕妇胎儿罹患严重的先天性综合征，并使成年人罹患自身免疫性疾病格林-巴利综合征。目前尚无针对寨卡病毒的临床批准疫苗或药物。这种未满足的医疗需求促使全球努力开发应对措施。几种有前途的寨卡病毒疫苗候选者已进入临床试验阶段。相比之下，寨卡病毒的抗病毒药物研发则落后了。在这里，我们综述了寨卡病毒药物发现的总体策略，包括（i）临床批准药物的再利用，（ii）基于病毒复制的抑制剂表型筛选，以及（iii）病毒蛋白的靶向药物发现。除了疫苗，抗病毒治疗的发展将提供一种控制寨卡病毒感染的补充手段。
Zotero 插件